Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat...
WF Mckay - EP
Milnacipran for the long-term treatment of fibromyalgia syndrome
The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the ...
SG Rao，M Gendreau，JD Kranzler - WO
Chronic pain, allodynia, hyperalgesia, fatigue, sleep disturbance, and depression; Central Sensitivity Syndrome; kits
The present invention provides methods of treating fibromyalgia or other diseases or conditions causing widespread pain and/or fatigue. In particular, the ...
MJ Roberts，S Pedder - US
Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products
The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C 1 -C 6 ...
S Cuisiat，A Newman-Tancredi，O Vitton，... - EP
ALPHA ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OF PAIN AND/OR INFLAMMATION
Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation.
ZANELLA John Myers，WAYNICK Sara D. - WO
Milnacipran; sub-class of dual serotonin norepinephrine reuptake inhibitors characterized by a non-tricyclic structure and inhibit the reuptake of norepine...
The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method ...
JD Kranzler，SG Rao - US
3-(phenoxyphenylmethyl)pyrrolidine compounds
where a and R 1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceut...
STANGELAND, Eric, L.，VAN DYKE, Priscilla，CHURCH, Timothy, J.，... - WO
Metamorphic Layers in Multijunction Solar Cells
A method of forming a multijunction solar cell comprising an upper subcell, a middle subcell, and a lower subcell comprising providing first substrate for the epitaxial growth of semiconductor material; forming a first solar subcell on s...
A Cornfeld，MA Stan - US
Modified release compositions of milnacipran
A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulat...
Jane C. Hirsh，Roman V. Rariy，S Chungi，... - US
Threo-DOPS controlled release formulation
The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that ...
S Peroutka，J Swarbrick - WO
